🇺🇸 FDA
Patent

US 11685906

Compositions and methods for treating ornithine transcarbamylase deficiency

granted A61KA61K48/00A61P

Quick answer

US patent 11685906 (Compositions and methods for treating ornithine transcarbamylase deficiency) held by ARCTURUS THERAPEUTICS, INC. expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCTURUS THERAPEUTICS, INC.
Grant date
Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K48/00, A61P, A61P9/00